Polar Asset Management Partners Inc. Mannkind Corp Transaction History

Polar Asset Management Partners Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.95 - $5.63 $390,406 - $556,452	-98,837 Reduced 23.19%	327,296 $1.34 Million
Q4 2022 Feb 14, 2023	SELL	$3.02 - $5.37 $4.17 Million - $7.42 Million	-1,381,300 Reduced 76.42%	426,133 $2.25 Million
Q3 2022 Nov 14, 2022	SELL	$2.99 - $4.35 $1.08 Million - $1.58 Million	-362,800 Reduced 16.72%	1,807,433 $5.59 Million
Q2 2022 Aug 15, 2022	BUY	$2.67 - $4.77 $4.16 Million - $7.43 Million	1,557,400 Added 254.13%	2,170,233 $8.27 Million
Q1 2022 May 16, 2022	BUY	$2.62 - $4.45 $513,258 - $871,755	195,900 Added 46.99%	612,833 $2.26 Million
Q4 2021 Feb 14, 2022	BUY	$4.05 - $5.37 $1.69 Million - $2.24 Million	416,933 New	416,933 $1.82 Million

244

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.57B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Polar Asset Management Partners Inc., based on Form 13F filings with the SEC.

Stay updated on Polar Asset Management Partners Inc. with notifications on news.